Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial

Background We report the final results of the randomized phase 2 FIGHT trial that evaluated bemarituzumab, a humanized monoclonal antibody selective for fibroblast growth factor receptor 2b (FGFR2b), plus mFOLFOX6 in patients with FGFR2b-positive (2 + /3 + membranous staining by immunohistochemistry...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2024-05, Vol.27 (3), p.558-570
Hauptverfasser:	Wainberg, Zev A., Kang, Yoon-Koo, Lee, Keun-Wook, Qin, Shukui, Yamaguchi, Kensei, Kim, In-Ho, Saeed, Anwaar, Oh, Sang Cheul, Li, Jin, Turk, Haci Mehmet, Teixeira, Alexandra, Hitre, Erika, Udrea, Adrian A., Cardellino, Giovanni Gerardo, Sanchez, Raquel Guardeño, Zahlten-Kümeli, Anita, Taylor, Kate, Enzinger, Peter C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Abdominal Surgery Adenocarcinoma Cancer Research Clinical outcomes Clinical trials ErbB-2 protein Gastric cancer Gastroenterology Immunohistochemistry Medicine Medicine & Public Health Metastases Metastasis Monoclonal antibodies NCT NCT03694522 Oncology Original Original Article Patients Placebo effect Placebos Surgical Oncology Survival analysis Tumor cells Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!